December 24, 2024 01:11 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
India refrains from commenting on extradition request for ousted Bengladeshi PM Sheikh Hasina | I don't blame Allu Arjun, ready to withdraw case: Pushpa 2 stampede victim's husband | Indian New Wave Cinema Architect Shyam Benegal dies at age 90 | Cylinder blast at a temple in Karnataka's Hubbali injures nine people | Kuwait PM personally sees off Modi at airport as Indian premier concludes two-day trip | Three pro-Khalistani terrorists, who attacked a police outpost in Gurdaspur, killed in an encounter | Who is Sriram Krishnan, an Indian-American picked by Donald Trump as US AI policy advisor? | Mohali building collapse: Death toll rises to 2, many feared trapped for 17 hours | 4-year-old killed after speeding car driven by a teen hits him in Mumbai | PM Modi attends opening ceremony of Arabian Gulf Cup in Kuwait
Govt allocates Rs 900 crore for r & d of Covid-19 vaccine

Govt allocates Rs 900 crore for r & d of Covid-19 vaccine

Nov 13, 2020, at 03:13 am

New Delhi/IBNS: Finance Minister Nirmala Sitharaman on Thursday announced Rs 900 crore for research and development for Covid-19 while also assuring that the funds will be allocated for the cost of vaccine and logistics as per requirement.

UNICEF to lead global procurement, supply of COVID vaccines

UNICEF to lead global procurement, supply of COVID vaccines

Sep 05, 2020, at 09:28 pm

New York: UN Children’s Fund (UNICEF) will be leading procurement and supply of COVID-19 vaccinations to ensure that all countries have safe, fast and equitable access to initial doses when they are available, the agency has announced.

Drug firm Moderna's COVID-19 vaccine shows positive result, share prices rise

Drug firm Moderna's COVID-19 vaccine shows positive result, share prices rise

May 18, 2020, at 11:34 pm

New York/IBNS: American biotech company Moderna Inc said its COVID-19 vaccine, which is still in the test phase, has shown success in a small initial trial with the vaccine producing virus-neutralising antibodies similar to that found in patients recovered from the infection, triggering a rise in its share prices by 25 per cent.